Title Content Date
Curetis erweitert Aufsichtsrat und Medizinischen Beirat Curetis N.V. (das "Unternehmen" und, zusammen mit Curetis GmbH, "Curetis"), ein Entwickler von neuartigen molekulardiagnostischen Lösungen, hat heute bekannt gegeben, dass das Unternehmen Dr. med. 12.04.2017
M+W Group names new CEO for the Americas Region M+W Group, a leading global high-tech engineering company, has announced that Rick Whitney will return to the company as Chief Executive Officer (CEO) for its Americas Region and President of the U 12.04.2017
Boost4Health at BIO-Europe Spring 2017 Biocat, a strategic agent in the development of the healthcare and life sciences ecosystem in Catalonia, and one of the Boost4Health partners, co-hosted BIO-Europe Spring 2017 in Barcelona from 20 03.04.2017
M+W Group Promotes Smart Lab Design at the Asia Pharma R&D Leaders Summit 2017 M+W Group was invited as a thought leadership company to participate in the Asia Pharma R&D Leaders Summit 2017, a key pharma R&D event in China, being 29.03.2017
Tracing down linear ubiquitination Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. 23.03.2017
M+W Group on a Successful Streak with Semiconductor Awards Leading global high-tech engineering company, M+W Group is celebrating their recent successes in semiconductor projects with awards in both China and Taiwan. 16.03.2017
New leadership at M+W Group Effective 1 March 2017, M+W Group has appointed a new Chief Executive Officer (CEO) and a new Chief Operating Officer (COO). 02.03.2017
Atriva receives seed financing to develop its next generation influenza therapeutic The next generation of Antiviral Therapies: Led by Stichting Participatie Atriva together with High-Tech Gründerfonds (HTGF), 14.02.2017
CureVac’s CEO, Ingmar Hoerr, Appointed by European Commission to High Level Group CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announced that the European Commission has appointed CureVac’s CEO, Ingmar Hoerr, Ph.D., as 23.01.2017
Amgen and immatics enter strategic collaboration to develop novel bispecific cancer immunotherapies Amgen (NASDAQ:AMGN) and Immatics Biotechnologies GmbH, a leading company in the field of cancer immunotherapy, today announced a research collaboration and exclusive license agreement to develop ne 09.01.2017